{"name":"Achilles Therapeutics","slug":"achilles-tx","ticker":"ACHL","exchange":"NASDAQ","domain":"achillestx.com","description":"Achilles Therapeutics is a clinical-stage oncology biotech company focused on developing novel cancer therapies. The company's pipeline includes several promising candidates, including its lead asset, ACT-542A. With a strong focus on precision medicine, Achilles Therapeutics aims to improve treatment outcomes for patients with cancer. The company is well-positioned to capitalize on the growing demand for targeted therapies in the oncology market.","hq":"London, United Kingdom","founded":0,"employees":"","ceo":"Iraj Ali","sector":"Clinical-Stage Oncology Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$65M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-03-14","type":"trial","headline":"Achilles Therapeutics Announces Positive Interim Data from Phase 1/2 Trial of ACT-542A","summary":"Achilles Therapeutics announced positive interim data from its Phase 1/2 trial of ACT-542A, a novel cancer therapy targeting tumor-specific neoantigens.","drugName":"ACT-542A","sentiment":"positive"},{"date":"2022-11-15","type":"deal","headline":"Achilles Therapeutics Enters into Collaboration with Merck KGaA","summary":"Achilles Therapeutics entered into a collaboration with Merck KGaA to develop and commercialize its cancer therapies, including ACT-542A.","drugName":"ACT-542A","sentiment":"positive"},{"date":"2022-08-16","type":"earnings","headline":"Achilles Therapeutics Reports Second Quarter 2022 Financial Results","summary":"Achilles Therapeutics reported its second-quarter 2022 financial results, with a focus on its pipeline progress and operational efficiency.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOUzVkSlg0b0xfZmdETktEWEJlN19LZTMzN0xjVl9KeG5JaHJXU0lhZ0VPeXlZS3hmLVVNWmJ0SXJjY3lGVUhzejljV1Y0TDlQVkJYWGZXSjJudWNVdERYS3pKanhmNFJMM1o0UWVKX1E3S1R6OWRxM2J2WkpkM3FmeDlLMVFFZWZyV3VWQk1pcUdlZldwUkE?oc=5","date":"2024-12-25","type":"pipeline","source":"Yahoo Finance","summary":"Achilles Therapeutics sells technology assets to AstraZeneca for $12M - Yahoo Finance","headline":"Achilles Therapeutics sells technology assets to AstraZeneca for $12M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxOZmQ3TFktemF3YnFDM3lYZ09XeFNPWmNtNGxfUzgtODJmSE80Yno4S3dkQTdkbWdSanJ6YTRYVXJqeVRQckZEQkIxSUZpVVpOT3J2Vy1zUTVwaHNCcERpdV9oZUR0Vy10eV9Ja0NfRjVGOFRzMkhlRXdqa0E3MEJsNzMyOWZ4ZGJRdVBUaHczUjI1Yzl2ZDJJV0E0bFhvV0Yyd3kyTHJEcmx1VnVSZmcyMUE0NjVUU1N4MTlfb2MzelRKVkRqWjRuSWVzZk9zWFR0WUcyVjgzZDQzRExq?oc=5","date":"2024-12-24","type":"pipeline","source":"globenewswire.com","summary":"Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca - globenewswire.com","headline":"Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxOaTRzNTIzLUpSTndkZ05ma001bmZkWFl0dlliMkxlM0ZBZzYxczk2ZGFDUURSRnd4bkxtTDFSc09KZUNwSXR5a2p0TnJrdkN0RVVuTTZibVlXMnNnX3NQRDRNbVZrVW5YSWhicGFhX3Q5dXRvVVBOa1JBdkdJWTBLMjhiMV9fMEQ0WUtXZzJtM0RULVJVUC1fa09SSUVGN0N0OFdvVElWeG5jM1ZHMXJxYWE3RXY4VVh4T09hZ01KVVBITHdJYmNSdmxWejBXT3pkbzZvNWxqLTc3bGw1X1JpQ3ZxQTZFS3hyM0Y5dGZ5c1YtUQ?oc=5","date":"2021-05-31","type":"deal","source":"PPF Group","summary":"Takeda exercised its option to acquire Maverick Therapeutics and its T cell engagers - PPF Group","headline":"Takeda exercised its option to acquire Maverick Therapeutics and its T cell engagers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPUW40U1EtOGhJa0pBVl9XVFIwZktuYlMyb2hDNXEzelNCZkZvWmVlZTVqal9xM3RLc0FxYTNfMDJkem42cnc4QXNwZS0zbHoxNXhvUTU0RmIwYmZRR0tUalk0dFA0cWdpVXhleE42a1J4QUNmejh4eFBYV1NiVDIwNF90dzh1clphVFB2TGVfWQ?oc=5","date":"2021-04-08","type":"pipeline","source":"pharmaphorum","summary":"Cancer Research UK spinout Achilles raises $175.5m in IPO - pharmaphorum","headline":"Cancer Research UK spinout Achilles raises $175.5m in IPO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTFB1RFlxa1V3bHZ2NndjRnQ5cFJKZWpKNHFCb2lGT090ZDRZT2E0cnNhTnBHQnNkRFE3Vm5BWW9MWUZvMlFHM3RTeGdESWRFenhOSC0tSHdmd01sUQ?oc=5","date":"2021-03-31","type":"pipeline","source":"MarketBeat","summary":"Achilles Therapeutics (ACHL) Stock Price, News & Analysis - MarketBeat","headline":"Achilles Therapeutics (ACHL) Stock Price, News & Analysis","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol-Myers Squibb","Merck & Co.","Roche Holding"],"therapeuticFocus":["Oncology","Precision Medicine"],"financials":null,"yahoo":null}